November 2, 2016

Transdermal PGE-1 Patch

In September 2016, AngioSoma, Inc. with its Chairman Emeritus David P. ‘Doc‘ Summers PhD filed 2 provisional U.S. Patents and 2 non-provisional U.S. Patents (announced October 11, 2016 in a press release entitled ‘AngioSoma, Inc. Files 3 New Patent Applications on Liprostin™‘; notice correction to 4 patents from 3 referenced in press release) for a:

Transdermal PGE-1 Patch

Transdermal PGE-1 Patch

A transdermal drug delivery system consisting of an adhesive patch for administration of a biologically active compound, said transdermal delivery patch comprising a matrix layer, wherein the matrix layer comprises: (i) a mixture of a liposomal, micro particulate, or mixture of both carrying a (2) transdermal delivery of prostaglandin (PGE-1), prostaglandin derivative, prostaglandin prodrug, or mixture of same, compounded and designed to dissolve through the skin of a mammal and release the drug into the blood stream for the treatment of cardiovascular diseases.”

These Patents are owned by AngioSoma Research, Inc. (Texas), a wholly owned subsidiary of AngioSoma, Inc. (a publicly traded Nevada corporation), and these patents are currently part of a Joint Venture with La Jolla Capital Partners LLC. announced October 5, 2016.

To put this simply, this ‘Transdermal PGE-1 Patch” is for the treatment of cardiovascular disease by delivery of PGE-1 or Liprostin™.


© 2016 by AngioSoma, Inc., all rights reserved.